← Oncology Approval Tracker

FDA DECISION ·

Aucatzyl

obecabtagene autoleucel · Autolus

FDA approvalNew therapyAcute lymphoblastic leukemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

LAMPGEN ANALYSIS

Why it matters

This CD19 CAR T product adds another cellular therapy option for adults with difficult-to-treat B-cell ALL.

What research teams should watch

Track pretreatment marrow blast burden and the resulting split-dose schedule; coordinate manufacturing, bridging and inpatient readiness.

PRIMARY RECORDS

Sources